Duffy血型基因多态性和结直肠癌的相关性研究

周世航; 王霓; 邵林楠; 于卫建; 张开立; 刘铭

doi:10.13201/j.issn.1004-2806-b.2020.06.003

Duffy血型基因多态性和结直肠癌的相关性研究

- 1. 大连市血液中心(辽宁大连, 116001);
- 2. 大连医科大学细胞生物学教研室
基金项目:
辽宁省自然基金指导计划(No:20180550393)

详细信息

通讯作者: 刘铭,E-mail:liuminglinxi@163.com

中图分类号: R457.1

收稿日期: 2019-10-17

Association of Duffy blood group gene polymorphism with colorectal cancer

- 1. Dalian Blood Center, Dalian, 116001, China;
- 2. Department of Cell Biology, Dalian Medical University

More Information

Corresponding author: LIU Ming, E-mail: liuminglinxi@163.com

Received Date: 17 October 2019

摘要

摘要: 目的:探讨Duffy血型基因多态性和结直肠癌的关系。方法:收集325例结直肠癌患者和306例健康对照人群血样,应用TaqMan-MGB探针实时PCR方法进行Duffy血型的基因分型。结果:在对照组人群中,基因型FY*A/FY*A为266例(86.9%),FY*A/FY*B为39例(12.7%),FY*B/FY*B为1例(0.3%)。在结直肠癌患者中,基因型FY*A/FY*A为286例(88.0%),FY*A/FY*B为38例(11.7%),FY*B/FY*B为1例(0.3%)。结直肠癌组和对照组比较,Duffy血型基因型频率分布差异无统计学意义(P＞0.05)。在淋巴结转移阴性的结直肠癌患者组FY*A/FY*B和FY*B/FY*B组合的基因型频率(16.7%)高于淋巴结转移阳性组的基因型频率(8.6%),而FY*A/FY*A的基因型频率(83.3%)要低于淋巴结转移阳性组的基因型频率(91.4%)(P＜0.05)。基因型FY*A/FY*A的结直肠癌患者要比非FY*A/FY*A基因型的患者发生淋巴结转移的风险高2.137倍。结论:Duffy血型基因多态性与结直肠癌发生无关,与结直肠癌的淋巴结转移有关。
- Duffy血型 /
- 结直肠癌 /
- 单核苷酸多态性
Abstract: Objective:To investigate the association of Duffy blood group gene polymorphism with colorectal cancer（CRC）. Method:Blood samples from patients with CRC and control group were collected and genotyped using real-time PCR with TaqMan-MGB probes. Result:The numbers of FY*A/FY*A,FY*A/FY*B and FY*B/FY*B genotype were 266（86.9%）,39（12.7%）and 1（0.3%）respectively in control group and 286（88.0%）,38（11.7%）and 1（0.3%）respectively in CRC.There were no significant differences（P＞0.05）in the genotype frequency distribution for Duffy blood gene between the patients and the control groups.Combination of FY*A/FY*B and FY*B/FY*B genotype frequencies（16.7%）in lymph node negative patients was higher than that in lymph node positive patients（8.6%）.However,FY*A/FY*A genotype frequency（83.3%）in lymph node negative patients was lower than that in lymph node positive patients（91.4%）（P＜0.05）.CRC patients with FY*A/FY*A genotype had higher lymph node metastasis risk（2.137-fold）than patients without FY*A/FY*A genotype.Conclusion:Duffy blood group gene polymorphism is not associated with CRC tumorigenesis but is correlated with lymph node metastasis.
- Duffy blood group /
- colorectal cancer /
- single nucleotide polymorphism

HTML全文

参考文献(18)

[1]	Jemal A,Bray F,Center MM et al.Global cancer statistics[J].CA Cancer J Clin,2011,61:69-90.
[2]	Sameer AS.Colorectal cancer:molecular mutations and polymorphisms[J].Front Oncol,2013,3:114.
[3]	Latini FRM,Bastos AU,Arnoni CP,et al.DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer[J].Blood Cells Mol Dis,2013,50:161-165.
[4]	Gai PP,van Loon W,Siegert K et al.Duffy antigen receptor for chemokines gene polymorphisms and malaria in Mangaluru,India[J].Malar J,2019,18:328.
[5]	Howes RE,Patil AP,Piel FB,et al.The global distribution of the Duffy blood group[J].Nat Commun,2011,2:266.
[6]	Yang C,Yu K-D,Xu W-H,et al.Effect of Genetic Variants in Two Chemokine Decoy Receptor Genes,DARC and CCBP2,on Metastatic Potential of Breast Cancer[J].PLoS One,2013,8:e78901.
[7]	Hou T,Liang D,Xu L,et al.Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer[J].Gynecol Oncol,2013,130:181-187.
[8]	Sun G,Wang Y,Zhu Y,et al.Duffy antigen receptor for chemokines in laryngeal squamous cell carcinoma as a negative regulator[J].Acta Otolaryngol,2011,131:197-203.
[9]	Wang J,Ou Z,Hou Y,et al.Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential[J].Oncogene,2006,25:7201-7211.
[10]	Zeng X-H,Ou Z-L,Yu K-D,et al.Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes[J].Breast Cancer Res Treat,2011,125:715-727.
[11]	Zhu Z,Sun Z,Wang Z,et al.Prognostic impact of atypical chemokine receptor expression in patients with gastric cancer[J].J Surg Res,2013,183:177-183.
[12]	Li DD,Yang C,Shao ZM,et al.Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer[J].Cancer Med,2018,7:5497-5504.
[13]	Zhu Q,Jiang L,Wang X.The expression of Duffy antigen receptor for chemokines by epithelial ovarian cancer decreases growth potential[J].Oncol Lett,2017,13:4302-4306.
[14]	Schnabel RB,Baumert J,Barbalic M,et al.Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators[J].Blood,2010,115:5289-5299.
[15]	Mangalmurti NS,Xiong Z,Hulver M,et al.Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation[J].Blood,2009,113:1158-1166.
[16]	Iiizumi M,Bandyopadhyay S,Watabe K.Interaction of Duffy antigen receptor for chemokines and KAI1:a critical step in metastasis suppression[J].Cancer Res,2007,67:1411-1414.
[17]	King CL,Adams JH,Xianli J,et al.Fya/Fyb antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria[J].Proc Natl Acad Sci U S A,2011,108:20113-20118.
[18]	Maeda S,Kuboki S,Nojima H et al.Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma[J].Cytokine,2017,95:12-21.